Novartis AG ADR (NVS)vsMolson Coors Brewing Co Class B (TAP)
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
TAP
Molson Coors Brewing Co Class B
$42.41
-1.67%
CONSUMER DEFENSIVE · Cap: $8.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 406% more annual revenue ($56.58B vs $11.19B). NVS leads profitability with a 23.9% profit margin vs -18.9%. NVS appears more attractively valued with a PEG of 2.59. TAP earns a higher WallStSmart Score of 56/100 (C).
NVS
Buy51
out of 100
Grade: C-
TAP
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Margin of Safety
+59.8%
Fair Value
$132.44
Current Price
$42.41
$90.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Earnings expanding 35.6% YoY
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
2.0% revenue growth
Expensive relative to growth rate
ROE of -18.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TAP
The strongest argument for TAP centers on Price/Book, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : TAP
The primary concerns for TAP are Revenue Growth, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while TAP is a turnaround play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
TAP is growing revenue faster at 2.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
TAP scores higher overall (56/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Molson Coors Brewing Co Class B
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
The Molson Coors Beverage Company, commonly known as Molson Coors, is a multinational drink and brewing company headquartered in Chicago in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?